Diana Becheru

Prof. Diana Becheru

University Politehnica of Bucharest
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DBDiana Becheru
Diana Becheru
GVGeorge M. Vlăsceanu
George M. Vlăsceanu
ABAdela Banciu
Adela Banciu
EVEugeniu Vasile
Eugeniu Vasile
Mariana IonitaMariana Ionita
Mariana Ionita
JBJorge Burns
Jorge Burns
A main challenge for optical graphene-based biosensors detecting nucleic acid is the selection of key parameters e.g. graphenic chemical structure, nanomaterial dispersion, ionic strength, and appropriate molecular interaction mechanisms. Herein we study interactions between a fluorescein-labelled DNA (FAM-DNA) probe and target single-stranded complementary DNA (cDNA) on three graphenic species, aiming to determine the most suitable platform for nucleic acid detection. Graphene oxide (GO), carboxyl graphene (GO-COOH) and reduced graphene oxide functionalized with PEGylated amino groups (rGO-PEG-NH2, PEG (polyethylene glycol)) were dispersed and characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). The influence of ionic strength on molecular interaction with DNA was examined by fluorescence resonance energy transfer (FRET) comparing fluorescence intensity and anisotropy. Results indicated an effect of graphene functionalization, dispersion and concentration-dependent quenching, with GO and GO-COOH having the highest quenching abilities for FAM-DNA. Furthermore, GO and GO-COOH quenching was accentuated by the addition of either MgCl2 or MgSO4 cations. At 10 mM MgCl2 or MgSO4, the cDNA induced a decrease in fluorescence signal that was 2.7-fold for GO, 3.4-fold for GO-COOH and 4.1-fold for rGO-PEG-NH2. Best results, allowing accurate target detection, were observed when selecting rGO-PEG-NH2, MgCl2 and fluorescence anisotropy as an advantageous combination suitable for nucleic acid detection and further rational design biosensor development.

29 May 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
RARoxana-Maria Amarandi
Roxana-Maria Amarandi
DBDiana Becheru
Diana Becheru
GVGeorge M. Vlăsceanu
George M. Vlăsceanu
Mariana IonitaMariana Ionita
Mariana Ionita
JBJorge Burns
Jorge Burns
Regenerative medicine is challenged by the need to conform to rigorous guidelines for establishing safe and effective development and translation of stem cell-based therapies. Counteracting widespread concerns regarding unproven cell therapies, stringent cell-based assays seek not only to avoid harm but also to enhance quality and efficacy. Potency indicates that the cells are functionally fit for purpose before they are administered to the patient. It is a paramount quantitative critical quality attribute serving as a decisive release criterion. Given a broad range of stem cell types and therapeutic contexts the potency assay often comprises one of the most demanding hurdles for release of a cell therapy medicinal product. With need for improved biomarker assessment and expedited measurement, recent advances in graphene-based biosensors suggest that they are poised to be valuable platforms for accelerating potency assay development. Among several potential advantages, they offer versatility for sensitive measurement of a broad range of potential biomarker types, cell biocompatibility for direct measurement, and small sample sufficiency, plus ease of use and point-of-care applicability.

29 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Augustin OfiteruAugustin Ofiteru
Augustin Ofiteru
DBDiana Becheru
Diana Becheru
SGSAMI GHARBIA
SAMI GHARBIA
CBCornel Balta
Cornel Balta
HHHildegard Herman
Hildegard Herman
JBJorge Burns
Jorge Burns
Potency assays are critical for regenerative medicine, addressing the known challenge of functional heterogeneity among human multipotent stromal cells (hMSC). Necessary laboratory cell expansion allows analysis before implantation in the patient. Levels of induction of five signature gene biomarkers, ALPL, COL1A2, DCN, ELN and RUNX2, constituted a previously reported proof-of-principle osteogenic potency assay. We tested assay modification to enhance reproducibility using six consistent bone marrow derived hBM-MSC and explored applicability to three adipose tissue derived hAT-MSC. Using a potent proprietary osteogenic induction factor, the GUSB/YWAHZ reference gene pair provided real time PCR consistency. The novel assay conditions supported the concept that genes encoding extracellular matrix proteins one week after osteogenic induction were informative. Nonetheless, relatively low induction of COL1A2 and ELN encouraged search for additional biomarkers. TGFB2 mRNA induction, important for osteogenic commitment, was readily quantifiable in both hBM-MSC and hAT-MSC. Combined with DCN, TGFB2 mRNA induction data provided discriminatory power for resolving donor-specific heterogeneity. Histomorphometric decorin and TGF-β2 protein expression patterns in eight-week heterotopic bone implants also discriminated the two non-bone-forming hMSC. We highlight progress towards prompt osteogenic potency assays, needed by current clinical trials to accelerate improved intervention with enhanced stem cell therapy for serious bone fractures.

1 March 2019
Verified
Conference Paper
Closed access
ABAdela Banciu
Adela Banciu
ACAndrei-Alexandru Calota
Andrei-Alexandru Calota
DBDiana Becheru
Diana Becheru
Bone fracture recovery is of major interest to society due to the increased incidence of trauma. Thus, the need to design an in vitro device for enhancing bone recovery under the influence of mechanical stimuli has emerged. We developed a device by 3D printing consisting of a cuvette with an elastic slide that can be deformed under the influence of a cantilever controlled by an electric motor. With this device, the influence of mechanical stimulation on preosteoblasts will be assessed. A potential in vitro preactivation of these cells could lead to the development of new cellular therapies for open fractures.